Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 3/20 | 0.41 |
| ▸ | METAP1 | P53582 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TDO2 | P48775 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL760383 | 0.83 | EGFR (0.62) | CDK2METAP2METAP1EGFRALDH1A1 | |
| Purine SCHEMBL5694230 | 0.81 | METAP2 (0.43) | CDK2METAP2METAP1EGFRALDH1A1 | |
| Quinoline SCHEMBL3706561 | 0.81 | ALDH1A1 (0.50) | CDK2METAP2METAP1EGFRALDH1A1 | |
| Purine SCHEMBL12003983 | 0.80 | ALDH1A1 (0.44) | CDK2METAP2METAP1ALDH1A1KDM4E | |
| Purine SCHEMBL30862524 | 0.80 | — | — | |
| Purine SCHEMBL29365913 | 0.80 | — | — | |
| Purine SCHEMBL3158 | 0.80 | — | — | |
| Purine SCHEMBL29703771 | 0.80 | ALDH1A1 (0.47) | CDK2METAP2METAP1ALDH1A1KDM4E | |
| Purine SCHEMBL2120554 | 0.80 | ALDH1A1 (0.47) | CDK2METAP2METAP1ALDH1A1KDM4E | |
| Purine SCHEMBL6421380 | 0.80 | ALDH1A1 (0.47) | CDK2METAP2METAP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| EP-2551270-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2019-06-12 | — | — | EP | disclosed |
| US-9493467-B2 | PI3 kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2015752-B1 | P13 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20140288096-A1 | P13 KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-25 | — | — | US | disclosed |
| US-8642604-B2 | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2004654-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2557080-A1 | Method for identifying pI3-kinase antagonists | The Regents of The University of California (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2551270-A2 | PYRAZOLOPYRMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | The Regents of The University of California (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20060252926-A1 | Process for the preparation of pregnanes | SICOR, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1474435-B1 | PROCESS FOR THE PREPARATION OF 6-ALPHA FLUORINATED PREGNANES | SICOR INC (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1474435-A1 | PROCESS FOR THE PREPARATION OF PREGNANES | Sicor Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| US-6784295-B2 | CARRIED OUT IN THE PRESENCE OF AN INORGANIC BASE OR ORGANIC NITROGEN BASE AND A PALLADIUM COMPLEX CATALYST CONTAINING SECONDARY MONOPHOSPHINES WITH ALIPHATIC, BRANCHED OR CYCLIC SUBSTITUENTS AS LIGANDS | SOLVIAS AG (CH) | 2004-08-31 | — | — | US | disclosed |
| WO-2004052911-A1 | PROCESS FOR THE PREPARATION OF PREGNANES | SICOR INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20030181688-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | INDOLESE ADRIANO (CH) | 2003-09-25 | — | — | US | disclosed |
| EP-1132361-B1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | SOLVIAS AG (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-6548684-B2 | Using monophosphine palladium complex catalyst | SOLVIAS AG (SE) | 2003-04-15 | — | — | US | disclosed |
| US-20010037042-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | SOLVIAS AG (CH) | 2001-11-01 | — | — | US | disclosed |
| EP-1132361-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | Solvias AG (CH) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037042-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | ADH1C, ALKBH3, PNMT | CDK2 2467/4885METAP2 2810/4885METAP1 3461/4885 |
| US-20030181688-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | ADH1C, ALKBH3, PNMT | CDK2 2467/4885METAP2 2810/4885METAP1 3461/4885 |
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | CDK2 198/4885METAP2 2516/4885METAP1 2524/4885 |
| US-20140288096-A1 | P13 KINASE ANTAGONISTS | AKT3, PRKD3, CDK13 | CDK2 136/4885METAP2 3131/4885METAP1 2302/4885 |
| US-20060252926-A1 | Process for the preparation of pregnanes | CYP17A1, CYP21A2, NR5A1 | CDK2 2611/4885METAP2 3136/4885METAP1 2682/4885 |
| US-20110301144-A1 | Kinase Antagonists | MTOR, RPS6KA3, AKT3 | CDK2 198/4885METAP2 2516/4885METAP1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.